p.75 抽出テキスト
CLINICAL STATEMENTS AND GUIDELINES Circulation. 2025;151:e771–e862. DOI: 10.1161/CIR.0000000000001309 April 1, 2025 e845 19 Pinto DS, Frederick PD, Chakrabarti AK, et al. Benefit of transferring ST- segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation. 2011;124:2512–2521. 20. Yamaguchi J, Matoba T, Kikuchi M, et al. Effects of door-in to door-out time on mortality among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention - systematic review and meta-analysis. Circ Rep. 2022;4:109–115. 21. Ward MJ, Vogus TJ, Bonnet K, et al. Breaking down walls: a qualitative evaluation of perceived emergency department delays for patients transferred with ST-elevation myocardial infarction. BMC Emerg Med. 2020;20:60. 22. Sinnaeve PR, Armstrong PW, Gershlick AH, et al. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation. 2014;130:1139–1145. 5.3.1. Timing and Choice of Agent for Fibrinolytic Therapy 1. Halvorsen S, Huber K. Fibrinolytic treatment of ST-elevation myocardial infarction. Update 2014. Hamostaseologie. 2014;34:47–53. 2. Koutsoukis A, Kanakakis I. Challenges and unanswered questions in STEMI management. Hellenic J Cardiol. 2019;60:211–215. 3. Gershlick AH, Westerhout CM, Armstrong PW, et al. Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. Heart. 2015;101:692–698. 4. Siddiqi TJ, Usman MS, Khan MS, et al. Meta-analysis comparing primary percutaneous coronary intervention versus pharmacoinvasive therapy in transfer patients with ST-elevation myocardial infarction. Am J Cardiol. 2018;122:542–547. 5. Fazel R, Joseph TI, Sankardas MA, et al. Comparison of reperfusion strategies for ST-segment-elevation myocardial infarction: a multivariate network meta-analysis. J Am Heart Assoc. 2020;9:e015186. 6. Bainey KR, Armstrong PW, Zheng Y, et al. Pharmacoinvasive strategy versus primary percutaneous coronary intervention in ST-elevation myocardial infarction in clinical practice: insights from the Vital Heart Response Registry. Circ Cardiovasc Interv. 2019;12:e008059. 7. Sinnaeve PR, Armstrong PW, Gershlick AH, et al. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation. 2014;130:1139–1145. 8. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Lancet. 1994;343:311–322. 9. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet. 1993;342:759– 766. 10. Langer A, Goodman SG, Topol EJ, et al. Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. (LATE Study Investigators). J Am Coll Cardiol. 1996;27:1327– 1332. 11. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation. 1996;94:891–898. 12. Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation. 2001;103:2862–2866. 13. Neuhaus KL, von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol. 1992;19:885– 891. 14. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997;95:351–356. 15. Jinatongthai P, Kongwatcharapong J, Foo CY, et al. Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with STsegment elevation myocardial infarction: a systematic review and network meta-analysis. Lancet. 2017;390:747–759. 16. Gunlu S, Demir M. Comparison of tenecteplase versus alteplase in STEMI patients treated with ticagrelor: a cross-sectional study. Am J Emerg Med. 2022;58:52–56. 17 Van De Werf F, Adgey J, Ardissino D, et al. Assessment of the Safety Ef- ficacy of a New Thrombolytic Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the AS- SENT-2 double-blind randomised trial. Lancet. 1999;354:716–722. 18. Global Use of Strategies to Open Occluded Coronary Arteries I. A compari- son of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118–1123. 5.3.2. Coronary Angiography and PCI After Fibrinolytic Therapy 1. Scheller B, Hennen B, Hammer B, et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol. 2003;42:634–641. 2. Le May MR, Wells GA, Labinaz M, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol. 2005;46:417–424. 3. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CA- RESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet. 2008;371:559–568. 4. Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360:2705– 2718. 5. Bohmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol. 2010;55:102–110. 6. Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. 2005;353:2758–2768. 7. Sutton AG, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol. 2004;44:287– 296. 8. Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction. A meta-analysis of randomized trials. J Am Coll Cardiol. 2007;49:422–430. 9. Collet JP, Montalescot G, Le May M, et al. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol. 2006;48:1326–1335. 10. Borgia F, Goodman SG, Halvorsen S, et al. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. Eur Heart J. 2010;31:2156– 2169. 11. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRA- CIA-1): a randomised controlled trial. Lancet. 2004;364:1045–1053. 12. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e18–e114. 13. de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol. 2001;38:1283–1294. 14. Sutton AG, Campbell PG, Price DJ, et al. Failure of thrombolysis by streptokinase: detection with a simple electrocardiographic method. Heart. 2000;84:149–156. 15. Mason PJ, Shah B, Tamis-Holland JE, et al. An update on radial artery access and best practices for transradial coronary angiography and intervention in acute coronary syndrome: a scientific statement from the American Heart Association. Circ Cardiovasc Interv. 2018;11:e000035. 16. Van de Werf F, Ristic AD, Averkov OV, et al. STREAM-2: half-dose tenecteplase or primary percutaneous coronary intervention in older patients with ST-segment-elevation myocardial infarction: a randomized, open-label trial. Circulation. 2023;148:753–764. 17. Abdel-Qadir H, Yan AT, Tan M, et al. Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis. Heart. 2015;101:1554–1561. 18. Fazel R, Joseph TI, Sankardas MA, et al. Comparison of reperfusion strate- gies for ST-segment-elevation myocardial infarction: a multivariate network meta-analysis. J Am Heart Assoc. 2020;9:e015186. Downloaded from http://ahajournals.org by on October 7, 2026